Injet Digital Aerosols

InJet Digital Aerosols Limited (IDAL), is a drug delivery systems company with intellectual property, including a strong patent portfolio, which enables the use of inkjets as aerosol pulmonary drug delivery devices. The worldwide market for drug delivery via the lungs is emerging as very significant and was forecast to exceed US$ 20 billion in 2005. To date, companies developing products for airway drug delivery have relied largely on inefficient mechanical or electro-mechanical systems. By owning key technology required to develop a unique family of digital pumps, IDAL is in a position to bring the next generation of products to the market.

In recent years Canon has made significant advances in bubble-jet technology towards generating a respirable 3µm aerosol. This is a critical achievement for the inhaler technology, expected to enable the delivery of aerosolized drug to the deep lung using bubble-jet technology, although there are still major technical challenges to be achieved in the commercialization.

IDAL remains focused on drug delivery systems through its agreement with Canon thereby maintaining its value for shareholders. The company will look to suitable liquidity opportunities in concert with the commercialization of the Canon device thus providing for shareholders’ liquidity in an investment with an enormous potential in a high growth market.

IDAL is a public non-listed company of which Viralytics has a 45% shareholding interest.

For further information on Injet Digital Aerosol, please visit their website at www.injet.com.au.